Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02426125
Title A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
Acronym RANGE
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Eli Lilly and Company
Indications
Therapies
Age Groups: adult
Covered Countries USA | TUR | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS


No variant requirements are available.